ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

xelox

Also written as “XELOX”, “IDX-1197+XELOX” and “SSGJ-706+Bevacizumab+XELOX”.

Its studies are mostly in Colorectal Neoplasms · Stomach Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 7 companies.

Drug pageXelox: every studyMany companies study it; this page follows only the 8 they lead. All 60 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Nov 13, 20068 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only21 open or runningphase 3since Nov 13, 2006Nov 13, 2006Nov 30, 2027phase 2 · NCT05702229
3SBio11 open or runningphase 2since Nov 14, 2025Nov 14, 2025Dec 2026phase 2 · NCT07233850
GlaxoSmithKlineits history only10 open or runningphase 1since Oct 11, 2006Oct 11, 2006none ahead
Hansoh Pharmaceutical Groupits history only11 open or runningphase 1since Sep 29, 2024Sep 29, 2024none ahead
Hoffmann-La Rocheits history only10 open or runningphase 3since Jul 6, 2006Jul 6, 2006none ahead
Idienceits history only11 open or runningphase 2since Jan 13, 2021Jan 13, 2021none ahead
Sichuan Luzhou Buchang Biopharmaceuticalits history only11 open or runningphase 1since Jan 2, 2025Jan 2, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of 3SBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2025First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT07233850 · 300 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Colorectal NeoplasmsNCT07233850

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study 3SBio leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07233850Colorectal Neoplasms · China2Not yet recruitingDec 2026300

How it is read

Names in the registry

  • “XELOX”, 2 entries
  • “IDX-1197+XELOX”, 1 entry
  • “SSGJ-706+Bevacizumab+XELOX”, 1 entry
  • “HS-20117+CAPEOX”, 1 entry
  • “BC001+Sintilimab+XELOX”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.